Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies

Next Previous
Trial Profile

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Inobrodib (Primary) ; Pomalidomide (Primary) ; Azacitidine; Elranatamab; Teclistamab; Venetoclax
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Richter's syndrome; T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors CellCentric

Most Recent Events

  • 07 Dec 2025 According to a CellCentric media release, new data from the dose-optimization cohorts of phase 2 clinical trial of inobrodib in combination with pomalidomide and dexamethasone in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM) were presented during a poster session at the American Society of Hematology (ASH) Annual Meeting.
  • 07 Dec 2025 Results presented in a CellCentric Media release
  • 03 Nov 2025 According to CellCentric Media release, additional arms on this trial investigating inobrodib in combination with elranatamab and teclistamab are currently ongoing and enrolling.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top